UCB Reports Positive Phase 3 Results for Epilepsy Drug Fenfluramine in Rare CDD Disorder BRUSSELS – Global biopharmaceutical company UCB announced Thursday that its drug fenfluramine (FINTEPLA®) showed positive results in a Phase 3 trial for treating CDKL5 deficiency disorder (CDD), a rare and severe developmental and epileptic encephalopathy. Dimitrios Bourikas, Global Medical Head for … Continue reading UCB Epilepsy Drug Fenfluramine Shows Positive Phase 3 Results